Responses
Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.